SUPERNUS PHARMACEUTICALS, INC. Total Assets

Quick Answer

SUPERNUS PHARMACEUTICALS, INC. reported Total Assets of $1.45 billion for the year ending 2025.

  • SUPERNUS PHARMACEUTICALS, INC. showed an increase of +6.2% in Total Assets from 2024 to 2025.
  • This data is from SUPERNUS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
  • XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2012: $43.20 million | Q2 2012: $79.97 million | Q3 2012: $67.01 million | Q1 2013: $79.06 million | Q2 2013: $131.97 million | Q3 2013: $123.77 million | Q1 2014: $97.52 million | Q2 2014: $94.19 million | Q3 2014: $126.33 million | Q1 2015: $139.64 million | Q2 2015: $154.17 million | Q3 2015: $166.77 million | Q1 2016: $194.47 million | Q2 2016: $218.63 million | Q3 2016: $285.12 million | Q1 2017: $322.26 million | Q2 2017: $346.37 million | Q3 2017: $385.48 million | Q1 2018: $825.16 million | Q2 2018: $852.80 million | Q3 2018: $922.51 million | Q1 2019: $1.03 billion | Q2 2019: $1.06 billion | Q3 2019: $1.11 billion | Q1 2020: $1.19 billion | Q2 2020: $1.49 billion | Q3 2020: $1.51 billion | Q1 2021: $1.51 billion | Q2 2021: $1.57 billion | Q3 2021: $1.56 billion | Q1 2022: $1.64 billion | Q2 2022: $1.69 billion | Q3 2022: $1.69 billion | Q1 2023: $1.79 billion | Q2 2023: $1.29 billion | Q3 2023: $1.29 billion | Q1 2024: $1.30 billion | Q2 2024: $1.32 billion | Q3 2024: $1.34 billion | Q1 2025: $1.35 billion | Q2 2025: $1.38 billion | Q3 2025: $1.42 billion.
  • Over the full 15 years of available data (2011 to 2025), SUPERNUS PHARMACEUTICALS, INC.'s Total Assets has grown by 2,603.6%.
  • Historical annual values: Fiscal year 2025: $1.45 billion | Fiscal year 2024: $1.37 billion | Fiscal year 2023: $1.28 billion | Fiscal year 2022: $1.70 billion | Fiscal year 2021: $1.69 billion | Fiscal year 2020: $1.50 billion | Fiscal year 2019: $1.16 billion | Fiscal year 2018: $977.81 million | Fiscal year 2017: $424.46 million | Fiscal year 2016: $309.57 million | Fiscal year 2015: $188.63 million | Fiscal year 2014: $137.51 million | Fiscal year 2013: $111.00 million | Fiscal year 2012: $93.99 million | Fiscal year 2011: $53.73 million.
  • Data sourced from SEC EDGAR public filings as of August 4, 2026.

Last verified: